Citadel Advisors »

Sab Biotherapeutics shares owned by Citadel Advisors

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Citadel Advisors from 13F filings

Historical chart of Citadel Advisors investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Citadel Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Citadel Advisors

Quarter filed Position value Share count Share price at filing
2024-09-30 $28k 10k 2.70

More positions owned by Citadel Advisors

Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
NVIDIA Corporation Call Option (NVDA)
Tesla Motors Call Option (TSLA)
Apple Call Option (AAPL)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Meta Platforms Cl A Call Option (META)
Microsoft Corporation Call Option (MSFT)
Amazon Call Option (AMZN)
Advanced Micro Devices Call Option (AMD)
Broadcom Call Option (AVGO)
Netflix Call Option (NFLX)
Alphabet Cap Stk Cl A Call Option (GOOGL)
Booking Holdings Call Option (BKNG)
Spdr Gold Tr Gold Shs Call Option (GLD)

View all positions for Citadel Advisors

Top funds holding Sab Biotherapeutics

BVF
Marshall Wace
Sessa Capital IM
Vanguard Group
HB Wealth Management
Geode Capital Management
Pathstone Holdings
First Manhattan
BlackRock
First PREMIER Bank
Kovitz Investment Group Partners
Institutional & Family Asset Management
BlackRock
Kestra Advisory Services
Citadel Advisors

View all funds holding Sab Biotherapeutics